ESR1 and breast carcinoma: Specifically, previous work studying KMT2C in mouse mammary stem cells suggested it to be tumor-promoting [47], while our own work on human ER+ breast cancer cells suggest KMT2C to be either tumor-suppressive or tumor-promoting, depending on hormone availability.